One Month of Wegovy: a realistic, step-by-step picture

Step 1, starting at 0.25 mg: the month that sets the foundation

Wegovy's titration schedule begins at 0.25 mg once weekly for the first four weeks. That figure surprises some people who have read about the 2.4 mg maintenance dose and expect to feel an immediate, dramatic difference. The starter dose is doing a specific job: it trains the gut to tolerate semaglutide before the dose climbs. Most prescribers describe it as the adjustment month rather than the treatment month.

What you are likely to notice at 0.25 mg is a modest reduction in appetite (enough that some meals feel naturally smaller) and possibly some nausea, particularly in the first day or two after each injection. According to the NHS medicines page for semaglutide, nausea, vomiting, diarrhoea and constipation are the most commonly reported effects, and they tend to be at their most noticeable when the dose is new or has just increased. For most people, injecting on the same day each week (abdomen, thigh or upper arm, sites rotated) quickly becomes routine.

Weight change in month one varies considerably between individuals. Some people see a small drop of a kilogram or two; others see little movement at all, which is entirely consistent with the medicine working as intended. Expecting the numbers from the full-dose trials to appear in week four is the most common source of early frustration. Understanding what Wegovy after one month typically looks like in terms of results can help set realistic expectations from the start.

Step 2, what the clinical trial evidence shows across a longer arc

Putting one month of Wegovy in context means looking at where the trajectory leads. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity for 68 weeks on semaglutide 2.4 mg alongside lifestyle changes. Average weight reduction at the end of the trial was around 15%. That figure accumulated over more than a year at full dose, not in a single month at the starter level.

Clinically meaningful weight loss in the STEP 1 data appeared to accelerate as doses increased through the 0.5 mg, 1.0 mg and 1.7 mg steps, with the most substantial changes occurring once participants reached maintenance. This is the reason prescribers assess progress across months rather than weeks. If you want a detailed look at how results build through the schedule, the one-month Wegovy weight-loss page covers the data in more depth.

Side effects also tend to follow the dose curve: GI symptoms are most common at the beginning of each new level and generally settle within a week or two. Fatigue, headache and dizziness appear less frequently but are worth noting. Rare but serious effects (pancreatitis in particular) require prompt attention; severe stomach pain that spreads to the back warrants same-day medical contact, as the MHRA has noted in its guidance on GLP-1 medicines. Patients can report any suspected side effect through the MHRA Yellow Card scheme.

Step 3, practical things that shape month one

A few practical details have an outsized effect on how smoothly the first month goes. Eating smaller, lower-fat meals (especially around injection day) reduces the chance of nausea becoming disruptive. Staying well hydrated matters more than it sounds: GI effects that cause fluid loss can compound fatigue. Alcohol tends to amplify GI symptoms and is better kept to a minimum in the early weeks.

The pen itself is pre-filled and simple to use. When it arrives, it comes in plain, unbranded packaging via tracked DPD delivery, and it goes straight into the fridge (2–8 °C). Each pen contains four weekly doses; the exact storage and in-use instructions are in the Patient Information Leaflet that comes with it, and those take precedence over any general guidance.

Month one is also the point at which most people settle on a consistent injection day and site-rotation pattern. Building that habit early makes the longer titration schedule considerably easier. Anyone on oral contraceptives should know that the NHS England guidance on weight-management injections recommends discussing contraception choice with a prescriber before starting, as GLP-1 medicines can affect absorption of the pill during early treatment; an additional barrier method is commonly advised for the first four weeks.

Step 4, what comes after the first month

At the end of four weeks the dose typically moves to 0.5 mg, then continues to climb in roughly monthly steps: 1.0 mg, 1.7 mg, and finally 2.4 mg (or, for eligible patients, the newer 7.2 mg maintenance dose approved by the MHRA in April 2026). Each step carries its own brief settling-in period, though most people find the later transitions easier than the first.

Progress reviews at each dose step are where the clinical relationship matters most. A prescriber looks at weight trend, tolerability and any new health information before confirming the next stage. If you are curious about how the picture develops, the second month of Wegovy brings the first real dose increase, and by month three many people are noticing more consistent appetite suppression as the dose climbs toward therapeutic range.

If you are considering starting, the full Wegovy overview covers eligibility, the complete titration pathway and how private access works in the UK. Many people also find it useful to check the current Wegovy price and what is included in the service before speaking to a prescriber. For a broader look at injectable and oral weight-loss options, the treatment page is a good starting point before speaking to a prescriber.